Patent details

LUC00076 Product Name: emicizumab et ses dérivés pharmaceutiquement acceptables (HEMLIBRA®)

Basic Information

Publication number:
LUC00076
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP118421452
Legal Status:
Inactive
Application number:
LUC00076
First applicant's nationality:
Procedural language:
French

Paediatric Extension

SPC Extension Filing Date:
28/09/2023
SPC Extension Agent Name:
OFFICE FREYLINGER S.A.
SPC Extension Status:
Granted
SPC Extension Grant Date:
21/10/2024
SPC Extension Rejection Date:

Marketing Authorization

Marketing Authorization Number:
EU/1/18/1271
Marketing Authorization Type:
Marketing Authorization Date:
27/02/2018
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
30/05/2018
First Marketing Authorization date:
27/02/2018
Grant date:
30/07/2018
Activation date:
Publication date:
31/05/2018
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
27/02/2033
SPC Extension Expiration:
27/08/2033
Rejection date:
Withdrawal date:

Owner

From:
30/05/2018
 
 

Name:
Chugai Seiyaku Kabushiki Kaisha
Address:
5-1, Ukima 5-chome, Kita-ku Tokyo 115-8543, Japan (JP)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
30/05/2018
Address:
PO Box 48, 8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2018/07
Publication date:
21/06/2018
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2018/09
Publication date:
23/08/2018
Description:
Section D : Granted supplementary protection certificates – I2 publication

3

Bulletin Heading:
SPCX1
Bulletin edition number:
2023/11
Publication date:
05/10/2023
Description:
Section G : Applications for extensions for pediatric use – I1E publication

4

Bulletin Heading:
SPCX2
Bulletin edition number:
2024/13
Publication date:
05/11/2024
Description:
Section H : Granted extensions for pediatric use of supplementary protection certificates – I2E publication

Annual Fees

Annual Fee Due Date:
01/12/2031
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
31/05/2018 Outgoing Correspondence 1
30/07/2018 Certificate 1
31/05/2018 Publication 1
30/05/2018 General Document 2
30/05/2018 General Document 3
30/07/2018 FNET_DC_FRONTPAGE 1
30/07/2018 Publication 1
30/05/2018 Application Form 4
28/09/2023 Marketing authorization 3
28/09/2023 Application Form 3
28/09/2023 Summary of the product caracteristics 143
28/09/2023 Outgoing Correspondence 1
28/09/2023 Paediatric investigation plan 2
28/09/2023 Publication 1
21/10/2024 Publication 1
21/10/2024 Certificate 1
28/09/2023 FNET_DC_FRONTPAGE 1
22/10/2024 Outgoing Correspondence 1